Elevated basic fibroblast growth factor levels in patients with pulmonary arterial hypertension

Jacques I. Benisty; Vallerie V. McLaughlin; Michael J. Landzberg; Jonathan D. Rich; Jane W. Newburger; Stuart Rich; Judah Folkman

doi:10.1378/chest.126.4.1255

Elevated basic fibroblast growth factor levels in patients with pulmonary arterial hypertension

Jacques I. Benisty^*, Vallerie V. McLaughlin, Michael J. Landzberg, Jonathan D. Rich, Jane W. Newburger, Stuart Rich, Judah Folkman

^*Corresponding author for this work

Medicine, Cardiology Division

Research output: Contribution to journal › Article › peer-review

76 Scopus citations

Abstract

Study objectives: Cellular growth in the vascular wall, including endothelial and smooth-muscle cell proliferation, is recognized as a component of the obstructive vasculopathy observed in the small vessels of the lungs in pulmonary arterial hypertension (PAH). We hypothesized that angiogenic growth factors may have a role in the molecular mechanisms underlying this cellular proliferation. Design: Case-control study. Setting: Multicenter, tertiary care hospitals. Participants: We studied 117 patients with PAH and 60 control subjects. Measurements: We measured levels of basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) in the blood and urine of these subjects using an enzyme-linked immunoassay. Results: Median levels of urinary and plasma bFGF were significantly higher in patients with PAH compared to normal control subjects. There was a difference in levels of urine and plasma bFGF according to etiology of pulmonary hypertension, with the highest levels seen in patients with primary pulmonary hypertension. Levels of urine or plasma VEGF were not significantly different between patients and control subjects. Conclusion: Patients with PAH have substantial alterations in urine and plasma levels of bFGF. This molecule may have a role as a mitogenic factor in the endothelial and smooth-muscle cell proliferation seen in PAH.

Original language	English (US)
Pages (from-to)	1255-1261
Number of pages	7
Journal	CHEST
Volume	126
Issue number	4
DOIs	https://doi.org/10.1378/chest.126.4.1255
State	Published - Oct 2004

Funding

This study was supported by a grant to Children's Hospital from EntreMed Inc., and by research grants to Dr. Benisty from the Pulmonary Hypertension Association (PHA/AHA-0020609H), and the Heart and Stroke Foundation of Canada/Canadian Institutes of Health Research. Dr. Benisty is a scholar of the Clinical Science Program at Harvard Medical School supported by a National Institutes of Health (National Heart, Lung, and Blood Institute) K30 grant (HL-04095).

Keywords

Angiogenesis
Growth substances
Pulmonary heart disease

ASJC Scopus subject areas

Critical Care and Intensive Care Medicine
Cardiology and Cardiovascular Medicine
Pulmonary and Respiratory Medicine

Access to Document

10.1378/chest.126.4.1255

Cite this

@article{04dae041cd1d49b4a9cf392e86a29a47,

title = "Elevated basic fibroblast growth factor levels in patients with pulmonary arterial hypertension",

abstract = "Study objectives: Cellular growth in the vascular wall, including endothelial and smooth-muscle cell proliferation, is recognized as a component of the obstructive vasculopathy observed in the small vessels of the lungs in pulmonary arterial hypertension (PAH). We hypothesized that angiogenic growth factors may have a role in the molecular mechanisms underlying this cellular proliferation. Design: Case-control study. Setting: Multicenter, tertiary care hospitals. Participants: We studied 117 patients with PAH and 60 control subjects. Measurements: We measured levels of basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) in the blood and urine of these subjects using an enzyme-linked immunoassay. Results: Median levels of urinary and plasma bFGF were significantly higher in patients with PAH compared to normal control subjects. There was a difference in levels of urine and plasma bFGF according to etiology of pulmonary hypertension, with the highest levels seen in patients with primary pulmonary hypertension. Levels of urine or plasma VEGF were not significantly different between patients and control subjects. Conclusion: Patients with PAH have substantial alterations in urine and plasma levels of bFGF. This molecule may have a role as a mitogenic factor in the endothelial and smooth-muscle cell proliferation seen in PAH.",

keywords = "Angiogenesis, Growth substances, Pulmonary heart disease",

author = "Benisty, {Jacques I.} and McLaughlin, {Vallerie V.} and Landzberg, {Michael J.} and Rich, {Jonathan D.} and Newburger, {Jane W.} and Stuart Rich and Judah Folkman",

note = "Funding Information: This study was supported by a grant to Children's Hospital from EntreMed Inc., and by research grants to Dr. Benisty from the Pulmonary Hypertension Association (PHA/AHA-0020609H), and the Heart and Stroke Foundation of Canada/Canadian Institutes of Health Research. Funding Information: Dr. Benisty is a scholar of the Clinical Science Program at Harvard Medical School supported by a National Institutes of Health (National Heart, Lung, and Blood Institute) K30 grant (HL-04095). ",

year = "2004",

month = oct,

doi = "10.1378/chest.126.4.1255",

language = "English (US)",

volume = "126",

pages = "1255--1261",

journal = "CHEST",

issn = "0012-3692",

publisher = "Elsevier Inc.",

number = "4",

}

TY - JOUR

T1 - Elevated basic fibroblast growth factor levels in patients with pulmonary arterial hypertension

AU - Benisty, Jacques I.

AU - McLaughlin, Vallerie V.

AU - Landzberg, Michael J.

AU - Rich, Jonathan D.

AU - Newburger, Jane W.

AU - Rich, Stuart

AU - Folkman, Judah

N1 - Funding Information: This study was supported by a grant to Children's Hospital from EntreMed Inc., and by research grants to Dr. Benisty from the Pulmonary Hypertension Association (PHA/AHA-0020609H), and the Heart and Stroke Foundation of Canada/Canadian Institutes of Health Research. Funding Information: Dr. Benisty is a scholar of the Clinical Science Program at Harvard Medical School supported by a National Institutes of Health (National Heart, Lung, and Blood Institute) K30 grant (HL-04095).

PY - 2004/10

Y1 - 2004/10

N2 - Study objectives: Cellular growth in the vascular wall, including endothelial and smooth-muscle cell proliferation, is recognized as a component of the obstructive vasculopathy observed in the small vessels of the lungs in pulmonary arterial hypertension (PAH). We hypothesized that angiogenic growth factors may have a role in the molecular mechanisms underlying this cellular proliferation. Design: Case-control study. Setting: Multicenter, tertiary care hospitals. Participants: We studied 117 patients with PAH and 60 control subjects. Measurements: We measured levels of basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) in the blood and urine of these subjects using an enzyme-linked immunoassay. Results: Median levels of urinary and plasma bFGF were significantly higher in patients with PAH compared to normal control subjects. There was a difference in levels of urine and plasma bFGF according to etiology of pulmonary hypertension, with the highest levels seen in patients with primary pulmonary hypertension. Levels of urine or plasma VEGF were not significantly different between patients and control subjects. Conclusion: Patients with PAH have substantial alterations in urine and plasma levels of bFGF. This molecule may have a role as a mitogenic factor in the endothelial and smooth-muscle cell proliferation seen in PAH.

AB - Study objectives: Cellular growth in the vascular wall, including endothelial and smooth-muscle cell proliferation, is recognized as a component of the obstructive vasculopathy observed in the small vessels of the lungs in pulmonary arterial hypertension (PAH). We hypothesized that angiogenic growth factors may have a role in the molecular mechanisms underlying this cellular proliferation. Design: Case-control study. Setting: Multicenter, tertiary care hospitals. Participants: We studied 117 patients with PAH and 60 control subjects. Measurements: We measured levels of basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) in the blood and urine of these subjects using an enzyme-linked immunoassay. Results: Median levels of urinary and plasma bFGF were significantly higher in patients with PAH compared to normal control subjects. There was a difference in levels of urine and plasma bFGF according to etiology of pulmonary hypertension, with the highest levels seen in patients with primary pulmonary hypertension. Levels of urine or plasma VEGF were not significantly different between patients and control subjects. Conclusion: Patients with PAH have substantial alterations in urine and plasma levels of bFGF. This molecule may have a role as a mitogenic factor in the endothelial and smooth-muscle cell proliferation seen in PAH.

KW - Angiogenesis

KW - Growth substances

KW - Pulmonary heart disease

UR - http://www.scopus.com/inward/record.url?scp=6344285687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6344285687&partnerID=8YFLogxK

U2 - 10.1378/chest.126.4.1255

DO - 10.1378/chest.126.4.1255

M3 - Article

C2 - 15486390

AN - SCOPUS:6344285687

SN - 0012-3692

VL - 126

SP - 1255

EP - 1261

JO - CHEST

JF - CHEST

IS - 4

ER -

Elevated basic fibroblast growth factor levels in patients with pulmonary arterial hypertension

Abstract

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this